Literature DB >> 29661900

Increased resting cerebral blood flow in adult Fabry disease: MRI arterial spin labeling study.

Po Phyu1, Aine Merwick1, Indran Davagnanam1, Fay Bolsover1, Fatima Jichi1, Claudia Wheeler-Kingshott1, Xavier Golay1, Deralynn Hughes1, Lisa Cipolotti1, Elaine Murphy1, Robin H Lachmann1, David John Werring2.   

Abstract

OBJECTIVE: To assess resting cerebral blood flow (CBF) in the whole-brain and cerebral white matter (WM) and gray matter (GM) of adults with Fabry disease (FD), using arterial spin labeling (ASL) MRI, and to investigate CBF correlations with WM hyperintensity (WMH) volume and the circulating biomarker lyso-Gb3.
METHODS: This cross-sectional, case-control study included 25 patients with genetically confirmed FD and 18 age-matched healthy controls. We quantified resting CBF using Quantitative Signal Targeting With Alternating Radiofrequency Labeling of Arterial Regions (QUASAR) ASL MRI. We measured WMH volume using semiautomated software. We measured CBF in regions of interest in whole-brain, WM, and deep GM, and assessed correlations with WMH volume and plasma lyso-Gb3.
RESULTS: The mean age (% male) for FD and healthy controls was 42.2 years (44%) and 37.1 years (50%). Mean whole-brain CBF was 27.56 mL/100 mL/min (95% confidence interval [CI] 23.78-31.34) for FD vs 22.39 mL/100 mL/min (95% CI 20.08-24.70) for healthy controls, p = 0.03. In WM, CBF was higher in FD (22.42 mL/100 mL/min [95% CI 17.72-27.12] vs 16.25 mL/100 mL/min [95% CI 14.03-18.48], p = 0.05). In deep GM, CBF was similar between groups (40.41 mL/100 mL/min [95% CI 36.85-43.97] for FD vs 37.46 mL/100 mL/min [95% CI 32.57-42.35], p = 0.38). In patients with FD with WMH (n = 20), whole-brain CBF correlated with WMH volume (r = 0.59, p = 0.006), not with plasma lyso-Gb3.
CONCLUSION: In FD, resting CBF is increased in WM but not deep GM. In FD, CBF correlates with WMH, suggesting that cerebral perfusion changes might contribute to, or result from, WM injury.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29661900      PMCID: PMC5902785          DOI: 10.1212/WNL.0000000000005330

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  28 in total

1.  Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.

Authors:  D F Moore; L T Scott; M T Gladwin; G Altarescu; C Kaneski; K Suzuki; M Pease-Fye; R Ferri; R O Brady; P Herscovitch; R Schiffmann
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

2.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

3.  White matter lesion severity in male and female patients with Fabry disease.

Authors:  A Fellgiebel; M J Müller; M Mazanek; K Baron; M Beck; P Stoeter
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

4.  Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities.

Authors:  A J Bastos-Leite; J P A Kuijer; S A R B Rombouts; E Sanz-Arigita; E C van Straaten; A A Gouw; W M van der Flier; P Scheltens; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2008-05-01       Impact factor: 3.825

5.  Selective arterial distribution of cerebral hyperperfusion in Fabry disease.

Authors:  D F Moore; P Herscovitch; R Schiffmann
Journal:  J Neuroimaging       Date:  2001-07       Impact factor: 2.486

6.  The vascular dementia of Fabry's disease.

Authors:  M F Mendez; T M Stanley; N M Medel; Z Li; D T Tedesco
Journal:  Dement Geriatr Cogn Disord       Date:  1997 Jul-Aug       Impact factor: 2.959

7.  The QUASAR reproducibility study, Part II: Results from a multi-center Arterial Spin Labeling test-retest study.

Authors:  Esben Thade Petersen; Kim Mouridsen; Xavier Golay
Journal:  Neuroimage       Date:  2009-08-04       Impact factor: 6.556

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

Review 9.  Cognitive dysfunction and depression in Fabry disease: a systematic review.

Authors:  Fay E Bolsover; Elaine Murphy; Lisa Cipolotti; David J Werring; Robin H Lachmann
Journal:  J Inherit Metab Dis       Date:  2013-08-16       Impact factor: 4.982

10.  Functional transcranial Doppler: presymptomatic changes in Fabry disease.

Authors:  Elsa Azevedo; Amélia Mendes; Daniela Seixas; Rosa Santos; Pedro Castro; Margarida Ayres-Basto; Bernhard Rosengarten; João Paulo Oliveira
Journal:  Eur Neurol       Date:  2012-05-04       Impact factor: 1.710

View more
  4 in total

Review 1.  Neuroimaging in Fabry disease: current knowledge and future directions.

Authors:  Sirio Cocozza; Camilla Russo; Giuseppe Pontillo; Antonio Pisani; Arturo Brunetti
Journal:  Insights Imaging       Date:  2018-11-02

2.  Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients.

Authors:  Sebastián Jaurretche; Germán Perez; Norberto Antongiovanni; Fernando Perretta; Graciela Venera
Journal:  Int J Chronic Dis       Date:  2019-06-24

3.  Structural disconnection and functional reorganization in Fabry disease: a multimodal MRI study.

Authors:  Ilaria Gabusi; Giuseppe Pontillo; Maria Petracca; Matteo Battocchio; Sara Bosticardo; Teresa Costabile; Alessandro Daducci; Chiara Pane; Eleonora Riccio; Antonio Pisani; Arturo Brunetti; Simona Schiavi; Sirio Cocozza
Journal:  Brain Commun       Date:  2022-07-22

4.  The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts.

Authors:  Cristina Chimenti; Patrizia Nencini; Federico Pieruzzi; Sandro Feriozzi; Renzo Mignani; Maurizio Pieroni; Antonio Pisani
Journal:  Orphanet J Rare Dis       Date:  2020-04-07       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.